Emcure Pharmaceuticals Valuation
| EMCURE Stock | 1,318 39.65 2.92% |
At this time, the firm appears to be overvalued. Emcure Pharmaceuticals shows a prevailing Real Value of USD962.32 per share. The current price of the firm is USD1318.25. Our model computes the value of Emcure Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 295.8 B, shares owned by institutions of 3.53 %, and Shares Owned By Insiders of 86.77 % as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 9.3858 | Enterprise Value 295.8 B | Enterprise Value Ebitda 22.4886 | Price Sales 3.9175 | Trailing PE 54.2911 |
Overvalued
Today
Please note that Emcure Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Emcure Pharmaceuticals is based on 3 months time horizon. Increasing Emcure Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Emcure Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Emcure Stock. However, Emcure Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1318.25 | Real 962.32 | Hype 1321.15 | Naive 1303.76 |
The real value of Emcure Stock, also known as its intrinsic value, is the underlying worth of Emcure Pharmaceuticals Company, which is reflected in its stock price. It is based on Emcure Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Emcure Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Emcure Pharmaceuticals helps investors to forecast how Emcure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Emcure Pharmaceuticals more accurately as focusing exclusively on Emcure Pharmaceuticals' fundamentals will not take into account other important factors: Emcure Pharmaceuticals Total Value Analysis
Emcure Pharmaceuticals is currently anticipated to have takeover price of 295.8 B with market capitalization of 270.98 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Emcure Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
295.8 B | 270.98 B |
Emcure Pharmaceuticals Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Emcure suggests not a very effective usage of assets in January.Emcure Pharmaceuticals Ownership Allocation
The market capitalization of Emcure Pharmaceuticals is USD270.98 Billion. Emcure Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 86.77 percent of Emcure Pharmaceuticals outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Emcure Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Emcure Pharmaceuticals and how it compares across the competition.
About Emcure Pharmaceuticals Valuation
The stock valuation mechanism determines Emcure Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Emcure Pharmaceuticals. We calculate exposure to Emcure Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Emcure Pharmaceuticals's related companies.Complementary Tools for Emcure Stock analysis
When running Emcure Pharmaceuticals' price analysis, check to measure Emcure Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emcure Pharmaceuticals is operating at the current time. Most of Emcure Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Emcure Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emcure Pharmaceuticals' price. Additionally, you may evaluate how the addition of Emcure Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |